CPT code 82016 represents a qualitative acylcarnitines laboratory test performed on plasma, serum, or urine to detect abnormal acylcarnitine profiles associated with inborn errors of metabolism. The test is clinically important as a component of newborn metabolic screening and for evaluating suspected metabolic disorders across age groups. Nationally, this code underpins lab-based diagnostic pathways that affect neonatal screening programs and specialist metabolic evaluations.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ordering the test, typical sites of service, and which payers commonly cover this type of laboratory service. The publication also summarizes benchmark considerations, common billing modifiers, and policy themes relevant to laboratory reimbursement and medical necessity criteria.

This article is written for a national audience of clinicians, billing professionals, and policy analysts. It provides concise background on the clinical utility of qualitative acylcarnitine testing, highlights payer coverage scope, and outlines what to expect in terms of administrative coding and policy direction. Data not available in the input are noted where applicable.